Bruce Seeley - CTi Biopharma President
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
President
Mr. Bruce J. Seeley is Chief Operating Officer of the company. Mr. Seeley assumed his role as the Companys Executive Vice President and Chief Commercial Officer in July 2015. Mr. Seeley previously served as Senior Vice President and General Manager, Diagnostics at NanoString Technologies, Inc. from May 2012 to March 2015. From October 2009 to March 2012, Mr. Seeley was Executive Vice President, Commercial, at Seattle Genetics, Inc. Prior to that, from August 2004 to October 2009, Mr. Seeley served in various commercial roles at Genentech, Inc. . From 1996 to 2004, Mr. Seeley held various roles at Aventis Pharmaceuticals Inc. in global and U.S. marketing, sales and new product commercialization and licensing. Prior to that, from 1991 to 1996, he served in sales at BristolMyers Squibb Company since 2017.
| Age | 52 |
| Tenure | 7 years |
| Phone | 206 282 7100 |
| Web | https://www.ctibiopharma.com |
CTi Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.2858) % which means that it has lost $0.2858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1875) %, meaning that it created substantial loss on money invested by shareholders. CTi Biopharma's management efficiency ratios could be used to measure how well CTi Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 49.96 M in liabilities. CTi Biopharma Corp has a current ratio of 3.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist CTi Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, CTi Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CTi Biopharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CTi to invest in growth at high rates of return. When we think about CTi Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Wael Hashad | Seres Therapeutics | N/A | |
| Eldon Mayer | Rigel Pharmaceuticals | 56 | |
| Carmen Betancourt | Cidara Therapeutics | N/A | |
| Michele Trucksis | Seres Therapeutics | 64 | |
| Marcus Chapman | Seres Therapeutics | 47 | |
| Daniel Hunt | Corvus Pharmaceuticals | 55 | |
| Michael Ferraresso | Verastem | N/A | |
| Esteban Masuda | Rigel Pharmaceuticals | 62 | |
| Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
| Yaron Naos | Protalix Biotherapeutics | 60 | |
| Jeffrey Stein | Cidara Therapeutics | 69 | |
| Monica Kleinman | Verastem | 35 | |
| Wendy Rieder | Madrigal Pharmaceuticals | 46 | |
| Erik Verner | Corvus Pharmaceuticals | 59 | |
| Thomas DesRosier | Seres Therapeutics | 63 | |
| Joseph Lobacki | Verastem | 59 | |
| Lucy Lu | Fortress Biotech | 39 | |
| Amy Broidrick | Viking Therapeutics | N/A | |
| Mehrdad Mobasher | Corvus Pharmaceuticals | N/A | |
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Gregory Zante | Viking Therapeutics | 53 | |
Management Performance
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 |
CTi Biopharma Corp Leadership Team
Elected by the shareholders, the CTi Biopharma's board of directors comprises two types of representatives: CTi Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CTi. The board's role is to monitor CTi Biopharma's management team and ensure that shareholders' interests are well served. CTi Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CTi Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Smith, VP Biometrics | ||
| James Fong, Ex Officer | ||
| Bruce Bennett, VP Operations | ||
| Laurent Fischer, Independent Director | ||
| Mary Mundinger, Independent Director | ||
| Adam Craig, President CEO, Director | ||
| Louis Bianco, Executive Vice President - Finance and Administration | ||
| Monique Greer, Senior Vice President of Corporate Communications and Investor Relations | ||
| Bruce Seeley, Executive Vice President and Chief Commercial Officer | ||
| MBA MD, CEO and President | ||
| Frederick Telling, Independent Director | ||
| Reed Tuckson, Independent Director | ||
| Ed Bell, Director - Investor Relations | ||
| David Parkinson, Independent Director | ||
| Jack Singer, Executive Vice President - Global Medical Affairs and Translational Medicine, Director | ||
| Michael Metzger, Director | ||
| James Bianco, President CEO, Director | ||
| Matthew Perry, Director | ||
| Matthew Plunkett, Chief Bus. Officer and Executive VP | ||
| Richard Love, Independent Director | ||
| John Volpone, Ex Staff | ||
| David Kirske, CFO, Executive Vice President | ||
| Phillip Nudelman, Independent Chairman of the Board | ||
| Nancy Boman, Senior Vice President of Clinical Development and Regulatory Affairs |
CTi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CTi Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 131.88 M | |||
| Shares Owned By Insiders | 5.49 % | |||
| Shares Owned By Institutions | 83.28 % | |||
| Number Of Shares Shorted | 11.27 M | |||
| Price To Earning | (1.68) X |
Pair Trading with CTi Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CTi Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CTi Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with CTi Stock
| 0.64 | CVI | CVR Energy Financial Report 6th of May 2024 | PairCorr |
Moving against CTi Stock
| 0.83 | BA | Boeing Earnings Call This Week | PairCorr |
| 0.59 | APAC | Stonebridge Acquisition Symbol Change | PairCorr |
| 0.52 | TRCA | Twin Ridge Capital | PairCorr |
| 0.5 | LION | Lionheart III Corp | PairCorr |
The ability to find closely correlated positions to CTi Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CTi Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CTi Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CTi Biopharma Corp to buy it.
The correlation of CTi Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CTi Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CTi Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CTi Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |